1. Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group.
- Author
-
Petterson, T. E., Gabriel, M., Tiedemann, K., Teague, L., Shaw, P. J., Baker, D., Bolton-Jones, R., Tapp, H., Oswald, C., Vowels, M. R., and O'Brien, T. A.
- Subjects
- *
CORD blood transplantation , *NEUTROPHILS , *BONE marrow transplantation , *DISEASE risk factors , *GRAFT versus host disease , *BONE marrow diseases , *PATIENTS , *THERAPEUTICS - Abstract
Unrelated umbilical cord blood (UCB) is an alternative stem cell source for paediatric patients lacking a matched related or unrelated marrow donor. We report the results of all paediatric unrelated UCB transplants performed in Australia and New Zealand over a 10-year period. A total of 135 patients were transplanted, 100 for malignant disease (74%) and 35 for non-malignant disorders. The majority (88%) of patients received an HLA-mismatched graft. The median infused total nucleated cell dose was 4.7 × 107/kg and CD34+ count 1.9 × 105/kg. Neutrophil engraftment occurred in 83% of patients by day 42 (median 23 days) and platelet engraftment in 55% by day 60 (median 56 days). Grades II–IV and III–IV acute GVHD occurred in 41 and 18% of patients, respectively. TRM and overall survival 1-year post transplant were 32 and 61%, respectively. A higher probability of neutrophil recovery (P=0.004) and faster time to recovery (median 18 days vs 26 days, P=0.008) were observed in recipients of a cord unit with a CD34 cell dose 1.7 × 105/kg. Our results support selection of cord units with CD34 cell doses 1.7 × 105/kg to promote faster engraftment, improve survival and lower TRM.Bone Marrow Transplantation (2009) 43, 207–215; doi:10.1038/bmt.2008.314; published online 22 September 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF